Home » Topics » BioWorld Science, Immune

BioWorld Science, Immune
RSS

FDA approves IND for phase IIb study of orismilast in patients with plaque psoriasis

Jan. 8, 2021

Topline data presented from phase III KEEPsAKE studies of risankizumab

Jan. 8, 2021

E.U. conditional marketing authorization for Moderna's COVID-19 vaccine

Jan. 7, 2021

New humanized murine model of myelofibrosis shows therapeutic vulnerability

Jan. 4, 2021

T-cell epitope-based COVID-19 vaccine EPV-CoV19 advances towards clinic

Jan. 4, 2021

New humanized graft-versus-host disease mouse model supports NK cell engraftment

Dec. 23, 2020

European Commission approves Palforzia to treat peanut allergy

Dec. 21, 2020

Phase II trials of ALX-629 begin in COVID-19, atopic asthma and psoriasis

Dec. 18, 2020

Heat Biologics completes ZVX-60 gp96-based COVID-19 vaccine cell line

Dec. 17, 2020

First subjects dosed in phase I study of PN-235

Dec. 17, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...